Page last updated: 2024-10-27

gliclazide and Cardiovascular Diseases

gliclazide has been researched along with Cardiovascular Diseases in 33 studies

Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.

Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.

Research Excerpts

ExcerptRelevanceReference
"High blood glucose level, lipid profile disturbances and plasma homocysteine (Hcy) are important risk factors for cardiovascular diseases in patients with type 2 diabetes."5.20Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus. ( Abd-Allah, GM; Hassan, MH, 2015)
"As compared with the patients receiving insulin monotherapy, the patients taking metformin alone or in combination showed a more effective recovery of carbohydrate and lipid metabolic disturbances, diminished insulin resistance (IR), lowered blood pressure and albuminuria, reduced diastolic dysfunction, and a smaller cardiovascular risk."5.14[Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus]. ( Elsukova, OS; Onuchin, SG; Onuchina, EL; Solov'ev, OV, 2010)
"Included were randomized studies of at least 12 weeks duration with the following outcomes: HbA1c change, incidence of severe hypoglycemia, weight change, cardiovascular events and/or mortality when comparing gliclazide with other oral blood glucose lowering drugs."4.90Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials. ( Bilo, HJ; de Bock, GH; Gans, RO; Groenier, KH; Houweling, ST; Kleefstra, N; Landman, GW; van Dijk, PR; van Hateren, KJ, 2014)
"Using nationwide administrative Danish registries, we followed all individuals without prior stroke or myocardial infarction who initiated metformin and an IS from 1997 through 2009."3.81Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study. ( Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A, 2015)
"Treatment with glibenclamide could be associated with higher mortality for cardiovascular diseases and malignancies, in comparison with gliclazide."3.74Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. ( Balzi, D; Barchielli, A; Buiatti, E; Lamanna, C; Mannucci, E; Marchionni, N; Masotti, G; Monami, M, 2007)
"Weight loss is strongly recommended for overweight and obese adults with type 2 diabetes."2.94The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE. ( Chalmers, J; Hamet, P; Harrap, S; Lee, AK; Marre, M; Mcevoy, JW; Ohkuma, T; Selvin, E; Sharrett, AR; Wang, D; Warren, B; Williams, B; Woodward, M, 2020)
"Severe hypoglycemia was strongly associated with increased risks of a range of adverse clinical outcomes."2.75Severe hypoglycemia and risks of vascular events and death. ( Billot, L; Chalmers, J; de Galan, BE; Grobbee, DE; Heller, S; Kengne, AP; Li, Q; MacMahon, S; Marre, M; Neal, B; Ninomiya, T; Patel, A; Woodward, M; Zoungas, S, 2010)
"In this cohort of men with type 2 diabetes, ED was associated with a range of CVD events."2.75Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial. ( Batty, GD; Chalmers, J; Czernichow, S; de Galan, BE; Hamet, P; Harrap, SB; Huxley, R; Li, Q; Neal, B; Patel, A; Poulter, N; Woodward, M; Zoungas, S, 2010)
"In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain."2.73Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. ( Billot, L; Bompoint, S; Chalmers, J; Cooper, M; de Galan, BE; Glasziou, P; Grobbee, D; Hamet, P; Harrap, S; Heller, S; Joshi, R; Liu, L; MacMahon, S; Mancia, G; Marre, M; Mogensen, CE; Neal, B; Pan, C; Patel, A; Poulter, N; Rodgers, A; Travert, F; Williams, B; Woodward, M, 2008)
"The primary aim must be the treatment of the insulin resistance."2.43[Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus]. ( Schumm-Draeger, PM, 2005)
"Gliclazide is a second-generation sulfonylurea that is widely used in the treatment of non-insulin-dependent diabetes mellitus (NIDDM)."2.38Gliclazide: metabolic and vascular effects--a perspective. ( Alberti, KG; Johnson, AB; Taylor, R, 1992)
"A post hoc analysis of patients with type 2 diabetes followed by the ADVANCE-ON (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation - Observational Study)."1.72Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients With Diabetes. ( Chalmers, J; Hamet, P; Harrap, S; Harris, K; Mancia, G; Poulter, N; Rodgers, A; Wang, N; Williams, B; Woodward, M; Zoungas, S, 2022)
"Glimepiride was associated with the best clinical outcome, showing the lowest mortality and lowest cardiovascular event risk of the five insulin secretagogues."1.51Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis. ( Huang, HK; Yeh, JI, 2019)
"The objective of this study was to determine if there is a dose-response relationship between sulfonylureas and major adverse cardiovascular events (MACE)."1.43Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes. ( Abdelmoneim, AS; Eurich, DT; Qiu, W; Senthilselvan, A; Simpson, SH, 2016)
" We sought to estimate individual beneficial and adverse effects of intensive glucose control in patients with type 2 diabetes."1.43Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. ( Chalmers, J; Grobbee, DE; Harrap, S; Heller, S; Mancia, G; Marre, M; Poulter, N; van der Graaf, Y; van der Leeuw, J; Visseren, FL; Woodward, M; Zoungas, S, 2016)
"In older patients with type 2 diabetes hospitalized for IHD, prior use of gliclazide, glyburide, or repaglinide appears to be associated with a similar risk of adverse cardiovascular sequelae."1.42Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. ( Abdelmoneim, AS; Huang, Y; Light, P; Qiu, W; Simpson, SH, 2015)
"gliclazide treatment."1.35Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. ( Khalangot, M; Kovtun, V; Kravchenko, V; Tronko, M, 2009)

Research

Studies (33)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (9.09)18.2507
2000's8 (24.24)29.6817
2010's18 (54.55)24.3611
2020's4 (12.12)2.80

Authors

AuthorsStudies
Wang, N1
Harris, K1
Hamet, P5
Harrap, S5
Mancia, G4
Poulter, N7
Williams, B3
Zoungas, S7
Woodward, M9
Chalmers, J9
Rodgers, A2
Kalra, S1
Lee, AK1
Wang, D1
Ohkuma, T2
Warren, B1
Sharrett, AR1
Marre, M4
Mcevoy, JW1
Selvin, E1
Tian, J1
Cooper, M3
Wang, JG1
Douros, A1
Yin, H1
Yu, OHY1
Filion, KB1
Azoulay, L1
Suissa, S1
Huang, HK1
Yeh, JI1
Bo, S1
Castiglione, A1
Ghigo, E1
Gentile, L1
Durazzo, M1
Cavallo-Perin, P1
Ciccone, G1
Konig, M1
Lamos, EM1
Stein, SA1
Davis, SN1
Landman, GW1
de Bock, GH1
van Hateren, KJ1
van Dijk, PR1
Groenier, KH1
Gans, RO1
Houweling, ST1
Bilo, HJ1
Kleefstra, N1
Erem, C1
Ozbas, HM1
Nuhoglu, I1
Deger, O1
Civan, N1
Ersoz, HO1
van der Leeuw, J2
Visseren, FL2
Kengne, AP3
van der Graaf, Y2
Glasziou, P2
MacMahon, S3
Grobbee, DE3
Mogensen, UM1
Andersson, C1
Fosbøl, EL1
Schramm, TK1
Vaag, A1
Scheller, NM1
Torp-Pedersen, C1
Gislason, G1
Køber, L1
Huang, Y1
Abdelmoneim, AS3
Light, P1
Qiu, W2
Simpson, SH3
Hassan, MH1
Abd-Allah, GM1
Hirakawa, Y1
Matthews, DR1
Patel, A4
Grobbee, R1
Jardine, M1
Eurich, DT1
Senthilselvan, A1
Heller, S3
Neal, B3
Billot, L2
Grobbee, D1
Liu, L1
Mogensen, CE1
Pan, C1
Bompoint, S1
de Galan, BE3
Joshi, R1
Travert, F1
Khalangot, M1
Tronko, M1
Kravchenko, V1
Kovtun, V1
Kassem, SA1
Raz, I1
Onuchin, SG1
Elsukova, OS1
Solov'ev, OV1
Onuchina, EL1
Bloomgarden, Z1
Li, Q2
Ninomiya, T1
Batty, GD1
Czernichow, S1
Huxley, R1
Harrap, SB1
Hasenbank, SE1
Seubert, JM1
Brocks, DR1
Light, PE1
Avogaro, A1
Khan, M1
Xu, Y1
Edwards, G1
Urquhart, R1
Mariz, S1
Schumm-Draeger, PM1
Betteridge, DJ1
Vergès, B1
Monami, M1
Balzi, D1
Lamanna, C1
Barchielli, A1
Masotti, G1
Buiatti, E1
Marchionni, N1
Mannucci, E1
Page, RC1
Harnden, KE1
Walravens, NK1
Onslow, C1
Sutton, P1
Levy, JC1
Hockaday, DT1
Turner, RC1
Cathelineau, G1
de Champvallins, M1
Bouallouche, A1
Lesobre, B1
Alberti, KG1
Johnson, AB1
Taylor, R1

Clinical Trials (12)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study[NCT00949286]8,494 participants (Actual)Observational2010-01-31Completed
ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation[NCT00145925]Phase 311,140 participants (Actual)Interventional2001-06-30Completed
Carotid Intimae-media Thickness (CIMT) and Carotid Plaque (CP) Presence as Risk Markers of Cardiovascular Disease at the Time of Type 2 Diabetes Diagnosis[NCT01898572]200 participants (Anticipated)Observational2012-01-31Active, not recruiting
Low-dose Colchicine Intervention in Patients With Type 2 Diabetes Mellitus and Microalbuminuria: Chongqing Study[NCT02035891]160 participants (Actual)Interventional2013-12-31Active, not recruiting
Effect of Anti-diabetic Drugs on Glycemic Variability. A Comparison Between Gliclazide MR (Modified Release) and Dapagliflozin on Glycemic Variability Measured by Continuous Glucose Monitoring (CGM) in Patients With Uncontrolled Type 2 Diabetes[NCT02925559]Phase 4135 participants (Actual)Interventional2016-10-31Completed
Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes[NCT02946632]Phase 3104 participants (Anticipated)Interventional2016-12-31Not yet recruiting
Dietary Intervention in Type-2 Diabetics and Pre-Diabetics Emphasizing Personalized Carbohydrate Intake[NCT02519309]465 participants (Actual)Interventional2015-08-31Completed
Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409]150 participants (Anticipated)Interventional2016-11-30Active, not recruiting
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705]Phase 4102 participants (Actual)Interventional2012-08-31Completed
Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.[NCT01991197]Phase 220 participants (Actual)Interventional2014-04-30Completed
A Comparison of Strict Glucose Control With Usual Care at the Time of Islet Cell Transplantation[NCT01123122]0 participants (Actual)Interventional2011-09-30Withdrawn
Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetic Patients With Coronary Artery Disease[NCT01604213]Phase 460 participants (Actual)Interventional2012-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline

The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention

Interventionpercentage (Mean)
Insulin Glargine, Metformin, Exenatide-2.43
Insulin Glargine, Metformin, Prandial Insulin0.44

HbA1C Levels

% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks

Intervention% of HbA1C (Mean)
Insulin Glargine, Metformin, Exenatide7.1
Insulin Glargine, Metformin, Prandial Insulin7.2

Number of Participants With Hypoglycemia

Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks

InterventionParticipants (Count of Participants)
Insulin Glargine, Metformin, Exenatide0
Insulin Glargine, Metformin, Prandial Insulin0

Weight Change During Trial

Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks

Interventionkg (Mean)
Insulin Glargine, Metformin, Exenatide-4.8
Insulin Glargine, Metformin, Prandial Insulin0.7

The Change in Levels of High Sensitivity C-reactive Protein From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

High sensitivity C-reactive protein (range 0 - no maximum) (NCT01991197)
Timeframe: 16 weeks

Interventionµg/ml (Median)
Sitagliptin0
Gliclazide8.4

The Change in Levels of Serum Glucose From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

The change in glucose from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks

Interventionmmol/L (Median)
Sitagliptin-0.2
Gliclazide-0.1

The Change in Levels of Systolic Blood Pressure From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

The change in systolic blood pressure from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks

InterventionmmHg (Median)
Sitagliptin4
Gliclazide-9

The Change in Levels of Total Cholesterol From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

The change in total cholesterol from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks

Interventionmmol/L (Median)
Sitagliptin0.1
Gliclazide-0.1

The Change in PASI From Baseline to 32 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to Patients Treated With Gliclazide.

Psoriasis area and severity index 0-72, higher score worse outcome (NCT01991197)
Timeframe: baseline and 32 weeks

Interventionscore on a scale (Median)
Sitagliptin3
Gliclazide1.8

The Change in the Psoriasis Area and Severity Index (PASI) From Baseline to 16 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to Patients Treated With Gliclazide.

Psoriasis area and severity index (0-72), higher scores worse outcome (NCT01991197)
Timeframe: 16 weeks

Interventionscore on a scale (Median)
Sitagliptin9.5
Gliclazide9.4

The Change in Weight From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

The change in weight from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks

Interventionkg (Median)
Sitagliptin-0.5
Gliclazide-0.6

The Effect of Treatment With Sitagliptin and With Gliclazide From Baseline to 16 Weeks on the Change in Dipeptidyl Peptidase-4 Levels in the Skin (in a Sub-group of Participants Willing to Undergo Skin Biopsies).

Dipeptidyl peptidase-4 levels levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks

InterventiondCt (Median)
Gliclazide-1.12
Sitagliptin0

The Effect of Treatment With Sitagliptin and With Gliclazide From Baseline to 16 Weeks on the Change in Interleukin-17 Levels in the Skin (in a Sub-group of Participants Willing to Undergo Skin Biopsies).

Interleukin 17 levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks

InterventiondCt (Median)
Sitagliptin3.41
Gliclazide2.09

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide From Baseline to 16 Weeks on Serum Levels Interleukin-17.

"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-17 (IL-17) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

Interventionpg/ml (Median)
Sitagliptin0
Gliclazide0

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide From Baseline to 16 Weeks on Serum Levels Interleukin-23.

"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-23 (IL-23) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

Interventionpg/ml (Median)
Sitagliptin0
Gliclazide0

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on the Change in Serum Leptin From Baseline to 16 Weeks.

"Secondary outcomes:~The change in serum concentrations of the adipokine leptin Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

Interventionpg/ml (Median)
Sitagliptin-0.07
Gliclazide0.43

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on the Serum Cytokine Tumour Necrosis Factor Alpha.

"Secondary outcomes:~The change in serum concentrations of the cytokines tumour necrosis factor alpha (TNFα) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

Interventionpg/ml (Median)
Sitagliptin0
Gliclazide0

The Number of Patricipants in the Sitagliptin and Gliclazide Arms With Adverse Events at 32 Weeks.

"Dosage: Sitagliptin: 100mg daily, or 50mg daily for participants with moderate kidney disease Gliclazide: 80-320 mg daily.~Secondary outcomes: the number participants with adverse events." (NCT01991197)
Timeframe: 32 weeks

InterventionParticipants (Count of Participants)
Sitagliptin6
Gliclazide10

The Change in Quality of Life Scores From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

"Dermatology life quality index (a skin related quality of life measure) (0-10), higher score worse outcome EQ-5D Euroqol 5 item quality of life index comprising 5 dimensions mobility, self-care, usual activities, pain, anxiety. An index can be derived from these 5 dimensions by conversion with a table of scores. The maximum score of 1 indicates the best health state and minimum score indicating the worst health outcome -0.594.~HADS Hospital anxiety and depression scale 0-16 for anxiety and 0-16 for depression, higher score worse outcome HAQ-8 Stanford 8 item disability scale. Scoring is from 0 (without any difficulty) to 3 (unable to do). The 8 scores from the 8 sections are summed and divided by 8. The result is the disability index (range 0-3 with 25 possible values). A" (NCT01991197)
Timeframe: 16 weeks

,
Interventionscore on a scale (Median)
DLQIHAQ-8HADS AnxietyHADS DepressionEQ-5D
Gliclazide-1.00.000-0.2
Sitagliptin0.00.0-100

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on Other Efficacy Endpoints.

"Secondary outcomes:~d. number or participants who acheived a greater than 50% reduction in PASI from baseline (PASI-50); e. number of participants who achieved PASI-75 and PASI-90." (NCT01991197)
Timeframe: 16 weeks

,
InterventionParticipants (Count of Participants)
PASI 50PASI 75PASI 90
Gliclazide100
Sitagliptin100

Reviews

7 reviews available for gliclazide and Cardiovascular Diseases

ArticleYear
An insight into the recent diabetes trials: what is the best approach to prevent macrovascular and microvascular complications?
    Current diabetes reviews, 2013, Volume: 9, Issue:5

    Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Typ

2013
Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials.
    PloS one, 2014, Volume: 9, Issue:2

    Topics: Administration, Oral; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2

2014
Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No.
    Diabetes care, 2009, Volume: 32 Suppl 2

    Topics: Administration, Oral; Cardiovascular Diseases; Diabetic Angiopathies; Disease Progression; Enzyme In

2009
Variations in tissue selectivity amongst insulin secretagogues: a systematic review.
    Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:2

    Topics: Animals; ATP-Binding Cassette Transporters; Carbamates; Cardiovascular Diseases; Cricetinae; Cyclohe

2012
Treating diabetes today with gliclazide MR: a matter of numbers.
    Diabetes, obesity & metabolism, 2012, Volume: 14 Suppl 1

    Topics: Antioxidants; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Ne

2012
[Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus].
    MMW Fortschritte der Medizin, 2005, Apr-28, Volume: 147, Issue:17

    Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Follow-Up Studies; Gli

2005
Gliclazide: metabolic and vascular effects--a perspective.
    Metabolism: clinical and experimental, 1992, Volume: 41, Issue:5 Suppl 1

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Gliclazide; Humans; Insul

1992

Trials

13 trials available for gliclazide and Cardiovascular Diseases

ArticleYear
The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE.
    The Journal of clinical endocrinology and metabolism, 2020, 01-01, Volume: 105, Issue:1

    Topics: Adult; Aged; Body-Weight Trajectory; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combin

2020
Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
    Diabetes care, 2020, Volume: 43, Issue:6

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2

2020
Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2014, Volume: 122, Issue:5

    Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypogly

2014
Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation.
    Hypertension (Dallas, Tex. : 1979), 2015, Volume: 65, Issue:1

    Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mell

2015
Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus.
    Pakistan journal of pharmaceutical sciences, 2015, Volume: 28, Issue:5

    Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combin

2015
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
[Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus].
    Terapevticheskii arkhiv, 2010, Volume: 82, Issue:8

    Topics: Blood Glucose; Carbohydrate Metabolism; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug The

2010
Severe hypoglycemia and risks of vascular events and death.
    The New England journal of medicine, 2010, Oct-07, Volume: 363, Issue:15

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla

2010
Severe hypoglycemia and risks of vascular events and death.
    The New England journal of medicine, 2010, Oct-07, Volume: 363, Issue:15

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla

2010
Severe hypoglycemia and risks of vascular events and death.
    The New England journal of medicine, 2010, Oct-07, Volume: 363, Issue:15

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla

2010
Severe hypoglycemia and risks of vascular events and death.
    The New England journal of medicine, 2010, Oct-07, Volume: 363, Issue:15

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla

2010
Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial.
    Journal of the American College of Cardiology, 2010, Nov-30, Volume: 56, Issue:23

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Delayed-A

2010
Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies.
    International journal of clinical practice, 2004, Volume: 58, Issue:10

    Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2;

2004
Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
    Diabetologia, 2005, Volume: 48, Issue:12

    Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2;

2005
'Healthy living' and sulphonylurea therapy have different effects on glucose tolerance and risk factors for vascular disease in subjects with impaired glucose tolerance.
    The Quarterly journal of medicine, 1993, Volume: 86, Issue:3

    Topics: Adolescent; Adult; Body Weight; Cardiovascular Diseases; Double-Blind Method; Exercise Therapy; Glic

1993
Management of newly diagnosed non-insulin-dependent diabetes mellitus in the primary care setting: effects of 2 years of gliclazide treatment--the Diadem Study.
    Metabolism: clinical and experimental, 1997, Volume: 46, Issue:12 Suppl 1

    Topics: Aged; Albuminuria; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Protocols; Cohort St

1997

Other Studies

13 other studies available for gliclazide and Cardiovascular Diseases

ArticleYear
Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients With Diabetes.
    Journal of the American College of Cardiology, 2022, 09-20, Volume: 80, Issue:12

    Topics: Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gliclazide; Heart Disease Risk F

2022
ADVANCE to ADVANCE-ON: Unfolding the "Legacy Story" in Diabetes.
    The Journal of the Association of Physicians of India, 2023, Volume: 71, Issue:8

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gliclazide; Humans; Insulin; Prospective Studies

2023
Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
    Diabetes care, 2017, Volume: 40, Issue:11

    Topics: Aged; Aged, 80 and over; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus

2017
Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
    Diabetes research and clinical practice, 2019, Volume: 152

    Topics: Aged; Carbamates; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angio

2019
Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
    European journal of endocrinology, 2013, Volume: 169, Issue:1

    Topics: Adult; Aged; Cardiovascular Diseases; Cause of Death; Cohort Studies; Confounding Factors, Epidemiol

2013
Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
    Diabetes research and clinical practice, 2015, Volume: 107, Issue:1

    Topics: Aged; Carbamates; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Drug Therapy, Combina

2015
Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.
    Journal of diabetes and its complications, 2015, Volume: 29, Issue:2

    Topics: Aged; Aged, 80 and over; Alberta; Blue Cross Blue Shield Insurance Plans; Carbamates; Cardiovascular

2015
Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:3

    Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopat

2016
Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes.
    Pharmacoepidemiology and drug safety, 2016, Volume: 25, Issue:10

    Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Re

2016
Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
    Diabetologia, 2016, Volume: 59, Issue:12

    Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combinations

2016
Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.
    Diabetes research and clinical practice, 2009, Volume: 86, Issue:3

    Topics: Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Cross-Secti

2009
Recent cardiovascular trials: what are the drivers of benefit and adverse effect?
    Journal of diabetes, 2009, Volume: 1, Issue:4

    Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetic Angiopathies; Gliclazide; Glycated Hemog

2009
Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality.
    Diabetes/metabolism research and reviews, 2007, Volume: 23, Issue:6

    Topics: Aged; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies;

2007